Caribou Shares Surge On Positive Data From Two Drug Studies

Dow Jones11-03

By Nicholas G. Miller

Shares of Caribou Biosciences surged after the company released positive data from studies of its treatment of Multiple Myeloma and its treatment of non-Hodgkin lymphoma.

The stock rose 46% to $3.52 in premarket trading after closing Friday up 52% this year.

Caribou said its treatment of Multiple Myeloma, called CB-011, delivered meaningful and durable responses and had a manageable safety profile in a phase 1 trial.

The company will begin dose expansion by the end of the year and share dose expansion data in 2026.

Caribou also said Monday that its phase one trial of its treatment for non-Hodgkin lymphoma, called Vispa-cel, demonstrated efficacy and durability and a well-tolerated safety profile.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

November 03, 2025 09:17 ET (14:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580219209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580219209","market":"other","top_or_hot":-1,"title":"Caribou Shares Surge On Positive Data From Two Drug Studies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> surged after the company released positive data from studies  of its treatment of Multiple Myeloma and its treatment of non-Hodgkin lymphoma. \n</p>\n<p>\n  The stock rose 46% to $3.52 in premarket trading after closing Friday up 52% this year. \n</p>\n<p>\n  Caribou said its treatment of Multiple Myeloma, called CB-011, delivered meaningful and durable responses and had a manageable safety profile in a phase 1 trial. \n</p>\n<p>\n  The company will begin dose expansion by the end of the year and share dose expansion data in 2026. \n</p>\n<p>\n  Caribou also said Monday that its phase one trial of its treatment for non-Hodgkin lymphoma, called Vispa-cel, demonstrated efficacy and durability and a well-tolerated safety profile. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 09:17 ET (14:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Shares Surge On Positive Data From Two Drug Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Shares Surge On Positive Data From Two Drug Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-03 22:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> surged after the company released positive data from studies  of its treatment of Multiple Myeloma and its treatment of non-Hodgkin lymphoma. \n</p>\n<p>\n  The stock rose 46% to $3.52 in premarket trading after closing Friday up 52% this year. \n</p>\n<p>\n  Caribou said its treatment of Multiple Myeloma, called CB-011, delivered meaningful and durable responses and had a manageable safety profile in a phase 1 trial. \n</p>\n<p>\n  The company will begin dose expansion by the end of the year and share dose expansion data in 2026. \n</p>\n<p>\n  Caribou also said Monday that its phase one trial of its treatment for non-Hodgkin lymphoma, called Vispa-cel, demonstrated efficacy and durability and a well-tolerated safety profile. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 09:17 ET (14:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRBU","symbol_name":"Caribou Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580219209","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580219209","pubTimestamp":1762179420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Caribou Biosciences surged after the company released positive data from studies  of its treatment of Multiple Myeloma and its treatment of non-Hodgkin lymphoma.The stock rose 46% to $3.52 in premarket trading after closing Friday up 52% this year.Caribou said its treatment of Multiple Myeloma, called CB-011, delivered meaningful and durable responses and had a manageable safety profile in a phase 1 trial.The company will begin dose expansion by the end of the year and share dose expansion data in 2026.Caribou also said Monday that its phase one trial of its treatment for non-Hodgkin lymphoma, called Vispa-cel, demonstrated efficacy and durability and a well-tolerated safety profile.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRBU":"Caribou Biosciences","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Caribou股价因两项药物研究的积极数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Caribou Biosciences surged after the company released positive data from studies  of its treatment of Multiple Myeloma and its treatment of non-Hodgkin lymphoma. \n\n\n  The stock rose 46% to $3.52 in premarket trading after closing Friday up 52% this year. \n\n\n  Caribou said its treatment of Multiple Myeloma, called CB-011, delivered meaningful and durable responses and had a manageable safety profile in a phase 1 trial. \n\n\n  The company will begin dose expansion by the end of the year and share dose expansion data in 2026. \n\n\n  Caribou also said Monday that its phase one trial of its treatment for non-Hodgkin lymphoma, called Vispa-cel, demonstrated efficacy and durability and a well-tolerated safety profile. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 09:17 ET (14:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580219209","isCrawlerRequest":true}